Abstract-We tested the ability of human mesenchymal stem cells (hMSCs) to deliver a biological pacemaker to the heart. hMSCs transfected with a cardiac pacemaker gene, mHCN2, by electroporation expressed high levels of Cs ϩ -sensitive current (31.1Ϯ3.8 pA/pF at Ϫ150 mV) activating in the diastolic potential range with reversal potential of Ϫ37.5Ϯ1.0 mV, confirming the expressed current as I f -like. The expressed current responded to isoproterenol with an 11-mV positive shift in activation. Acetylcholine had no direct effect, but in the presence of isoproterenol, shifted activation 15 mV negative. Transfected hMSCs influenced beating rate in vitro when plated onto a localized region of a coverslip and overlaid with neonatal rat ventricular myocytes. The coculture beating rate of 93Ϯ16 bpm when hMSCs were transfected with control plasmid (expressing only EGFP) and 161Ϯ4 bpm when hMSCs were expressing both EGFPϩmHCN2 (PϽ0.05). We next injected 10 6 hMSCs transfected with either control plasmid or mHCN2 gene construct subepicardially in the canine left ventricular wall in situ. During sinus arrest, all control (EGFP) hearts had spontaneous rhythms (45Ϯ1 bpm, 2 of right-sided origin and 2 of left). In the EGFPϩmHCN2 group, 5 of 6 animals developed spontaneous rhythms of left-sided origin (rateϭ61Ϯ5 bpm; PϽ0.05). Moreover, immunostaining of the injected regions demonstrated the presence of hMSCs forming gap junctions with adjacent myocytes. These findings demonstrate that genetically modified hMSCs can express functional HCN2 channels in vitro and in vivo, mimicking overexpression of HCN2 genes in cardiac myocytes, and represent a novel delivery system for pacemaker genes into the heart or other electrical syncytia. 
A lthough electronic pacemakers are currently the mainstay of therapy for heart block and other electrophysiological abnormalities, they are not optimal. Among their shortcomings are limited battery life, the need for permanent catheter implantation into the heart, and lack of response to autonomic neurohumors. 1 For these reasons, several gene therapy approaches have been explored as potential alternatives. These include either overexpression of ␤ 2 -adrenergic receptors, 2,3 use of a dominant-negative construct to suppress inward rectifier current when expressed together with the wild-type gene Kir2.1, 4 and implantation of vectors carrying the pacemaker gene, HCN2, into atrium 5 or bundle branch system. 6 A problem inherent in some of these approaches [2] [3] [4] [5] [6] is the use of viruses to deliver the necessary genes. Although the vectors have been replication-deficient adenoviruses that have little infectious potential, these incorporate the possibility of only a transient improvement in pacemaker function as well as potential inflammatory responses. The use of retroviruses and other vectors, although not attempted as yet for biological pacemakers, carries a risk of carcinogenicity and infectivity that is unjustified, given the current success of electronic pacemakers. Attempts to use embryonic human stem cells to create pacemakers are still in their infancy and carry the problems of identifying appropriate cell lineages, the possibility of differentiation into lines other than pacemaker cells, and potential for neoplasia (see overview 7 ) .
With this in mind, we embarked on a project to test proof-of-principle that genetically engineered adult human mesenchymal stem cells (hMSCs) can serve as a platform for carrying the pacemaker gene to the heart. We did this with the understanding that the potential for differentiation into other cell lines exists for hMSCs as for embryonic stem cells, but with the rationale that if the relevant gene is genetically overexpressed then the presence or absence of differentiation may be less important. Further, in testing proof-of-principle, we did not attempt to test the long-term safety of engineered hMSCs, which has yet to be demonstrated.
In this study, we demonstrate that hMSCs are effectively transfected by electroporation with a vector construct directing the expression of mouse HCN2 (mHCN2) as well as EGFP, and are capable of expressing functional mHCN2 channels in vitro. HCN2 expression in hMSCs provides an I f -based current sufficient to change the beating rate of cocultured neonatal rat ventricular myocytes, and to drive the canine ventricle, mimicking the HCN2 overexpression by adenoviral constructs. 5 We demonstrate that hMSCs make connexin proteins and form functional gap junctions that couple electrically with canine cardiac myocytes. Thus, we have developed an ex vivo gene therapy system using genetically modified hMSCs as a platform for delivery of pacemaker genes into the heart.
Materials and Methods
Protocols were reviewed and approved by the Columbia University institutional animal care and use committee.
Human Mesenchymal Stem Cell Maintenance and Transfection
Human mesenchymal stem cells (Poietics hMSC; mesenchymal stem cells, human bone marrow) were purchased from Clonetics/BioWhittaker (Walkersville, Md) and cultured in MSC growing medium (Poietics MSCGM; BioWhittaker) at 37°C in a humidified atmosphere of 5% CO 2 . Cells were used from passages 2 to 4. A full-length mHCN2 cDNA was subcloned into a pIRES2-EGFP vector (BD Biosciences Clontech). Cells were transfected by electroporation using the Amaxa Biosystems Nucleofector (Amaxa) technology. 8 Expression of EGFP after 24 to 48 hours revealed transfection efficiency of 30% to 45%.
Patch-Clamp Studies of I HCN2 Expressed in hMSCs
We used whole-cell patch clamp to study membrane currents in control hMSCs and those transfected with mHCN2, the gene encoding the ␣-subunit of the pacemaker current, I f . Expressed I f (ie, I HCN2 ) was measured under voltage-clamp by an Axopatch-1B (Axon Instruments) amplifier. Patch electrode resistance was 4 to 6 M⍀ before sealing. Cells were constantly superfused using a gravitational perfusion system with a complete change of the chamber solutions in about 0.5 minutes. The temperature of the bath as well as of the perfusion solution was kept constant at 35Ϯ0.5°C. The pipette solution was filled with (in mmol/L) KCl 50, K-aspartate 80, MgCl 2 1, Mg-ATP 3, EGTA 10, and HEPES 10 (pH adjusted to 7.2 with KOH). The external solution contained (in mmol/L) NaCl 137.7, KCl 5.4, NaOH 2.3, CaCl 2 1.8, MgCl 2 1, Glucose 10, HEPES 5, and BaCl 2 2 (pH adjusted to 7.4 with NaOH). The membrane capacity was measured by applying a voltage clamp step and current densities are expressed as the value of peak current per capacity.
Dual Patch-Clamp Studies of Gap Junctions
Canine cardiac ventricular myocytes were isolated as previously described. 9 Primary cultures of the myocytes were maintained using procedures described for mouse myocytes. 10 They were plated at 0.5 to 1ϫ10 4 cells/cm 2 in MEM containing 2.5% fetal bovine serum (FBS) and 1% PS onto mouse laminin (10 g/mL) precoated coverslips. After 1 hour of culture in a 5% CO 2 incubator at 37°C, the medium was changed to FBS-free MEM. hMSCs were added and coculture was maintained in DMEM with 5% FBS. Cell Tracker green (Molecular Probes) was used to distinguish hMSCs from HeLa cells in coculture in all experiments. 11 Glass coverslips with adherent cells were transferred to an experimental chamber perfused at room temperature (Ϸ22°C) with bath solution containing (in mmol/L) NaCl 150, KCl 10, CaCl 2 2, HEPES 5 (pH 7.4), and glucose 5. The patch pipettes were filled with solution containing (in mmol/L) K ϩ aspartate Ϫ 120, NaCl 10, MgATP 3, HEPES 5 (pH 7.2), and EGTA 10 (pCa Ϸ8), filtered through 0.22-m pores. When filled, the resistance of the pipettes measured 1 to 2 M⍀. Experiments were performed on cell pairs using a double voltage-clamp. This method permitted us to control the membrane potential (V m ) and measure the associated junctional currents (I j ).
Action Potential Recordings in Coculture
hMSCs were plated onto fibronectin-coated 9ϫ22-mm coverslips, using a cloning cylinder to restrict the initial plating to an approximate 4-mm diameter circular area. The cells expressed either EGFP alone or EGFPϩmHCN2. Four hours later, the cloning cylinder was removed and neonatal rat ventricular myocytes, prepared as described previously, 12 were plated over the entire coverslip. Four to five days later, the coverslips were placed in a superfusion chamber maintained at 35°C and action potentials recorded from near the center of the coverslip using a perforated patch electrode 12 The perforated patch technique was used, and amphotericin B (400 g/mL, Sigma) was added to the pipette solution.
In Vivo Studies in Canine Ventricle
Stem cells were prepared as above. Under sterile conditions, after sodium thiopental induction (17 mg/kg IV) and inhalational isoflurane (1.5 to 2.5%) anesthesia, 23-to 27-kg mongrel dogs were subjected to a pericardiectomy. We injected 10 6 hMSCs containing HCN2ϩGFP or GFP alone subepicardially in 0.6 mL of solution into the left ventricular anterior wall, approximately 2 mm deep to the epicardium via a 21-gauge needle. Animals recovered for 4 to 10 days, during which their cardiac rhythms were monitored. They then were anesthetized with isoflurane, as above. Both cervical vagal trunks were isolated, the chest opened, and ECGs monitored. Graded right and left vagal stimulation was performed via standard techniques 13 to suppress sinus rhythm such that escape pacemaker function might occur. Tissues were then removed for histological study.
Histological Methods
Unless otherwise indicated, samples of heart tissue were fixed in 10% buffered formalin, embedded in paraffin and sectioned at 4 or 6 micrometers. Some formalin-fixed sections were stained in a routine fashion with hematoxylin and eosin (H&E). Monoclonal mouse antibodies (DakoCytomation) raised against the vimentin and human CD 44 were used applying an avidin-biotin-peroxidase method. 14 Tissues stained immunohistochemically were then counterstained with hematoxylin. We used positive and negative controls for immunohistochemical staining. hMSCs were distinguished from fibroblasts by CD 44 staining. The vimentin antibody intensely stains hMCSs but also stains most mesenchymal tissue. Other sections were treated to remove wax and rehydrated by exposure to xylene for 6 minutes with three rinses followed by similar exposures to 100%, 95%, 50% ethanol, deionized water, and PBS. The sections were then exposed to 30% hydrogen peroxide for 10 minutes and were again rinsed in PBS for 50 minutes. The rehydrated sections were exposed to a 0.01 mol/L citrate buffer, which was heated to a boil for 10 minutes and then allowed to cool to room temperature. Polyclonal antibodies raised against connexin 43 (Cx43; Zymed Laboratories Inc) were used.
Statistics
Results are presented as meanϮSEM. Statistical significance was determined by Student's t test for unpaired data. A value of PϽ0.05 was considered significant.
Results

Transfection of hMSCs With mHCN2 and Demonstration of Pacemaker Current
Nontransfected hMSCs demonstrated no significant timedependent currents during hyperpolarizations ( Figure 1A ). MHCN2-transfected hMSCs expressed a large timedependent inward current activating on hyperpolarizations up to Ϫ160 mV and deactivating during the following step to 20 mV ( Figure 1B ). Figure 1C shows the I f activation curve constructed from tail currents recorded in mHCN2-transfected hMSCs (see inset for sample currents). We fit the data with a Boltzmann two-state model, which yielded a midpoint (V 50 ) of Ϫ91.8Ϯ0.9 mV and a slope factor of 8.8Ϯ0.5 mV (nϭ9), similar to values for mHCN2 expression in oocytes and HEK 293 cells. 15, 16 These values are an approximation because the I f current density was large and its slow rundown was apparent, as in all other preparations. The results suggest I f should be activated at diastolic potentials in the hMSCs if they are well coupled by gap junctions to ventricular myocytes. To confirm the expressed current was I f , we executed the experiments illustrated in Figure 2 ]. 17 We also tested the effect of Cs ϩ to block the expressed current. Cs ϩ (4 mmol/L) reversibly blocked the inward currents but had little effect on the outward deactivating tail currents, consistent with Cs ϩ blockade of I f . 18 We constructed the fully activated I-V relationships for the I f -like current in Figure 2D . The plot reinforces the two major observations from the raw data. gives a midpoint of Ϫ91.8Ϯ0.9 mV and a slope of 8.8Ϯ0.5 mV (nϭ9). I f was fully activated around Ϫ140 mV with an activation threshold of Ϫ60 mV. Inset shows representative tail currents used to construct I f activation curves. Voltage protocol was to hold at Ϫ30 mV and hyperpolarize for 1.5 seconds to voltages between Ϫ40 and Ϫ160 mV in 10-mV increments followed by a 1.5-second voltage step to ϩ20 mV to record the tail currents. Voltage protocol was to hold at Ϫ30 mV and hyperpolarize to Ϫ150 mV for 2 seconds followed by a 1.5-second depolarization to voltages between Ϫ150 and ϩ20 mV to record the tail currents necessary to construct the fully activated current-voltage relation followed by a 0.5-second step to Ϫ10 mV.
First, inward but not outward I f -like currents are blocked by Cs ϩ , and second, the zero current indicates a mixed selectivity consistent with the known properties of I f . In a separate protocol I f density at Ϫ150 mV was 31.1Ϯ3.8 pA/pF (nϭ17). Membrane capacity for the transfected hMSCs was 110.8Ϯ9.0 pF (nϭ17).
Neurohumoral Regulation of I HCN2
A potential advantage of biological over electronic pacemakers is their hormonal regulation. We therefore examined the effects of ␤-adrenergic and muscarinic agonists on I f recorded in the hMSCs (Figures 3 and 4) . Figures 3A and 3B demonstrate that the currents at Ϫ80 and Ϫ100 mV in isoproterenol are larger than those in control, whereas the currents in both conditions are almost equal at Ϫ160 mV. This voltage-dependent difference is expected for a shift in the activation curve ( Figure 3D ). The half activation voltage (V 50 ) was Ϫ96Ϯ0.9 mV in control and Ϫ84.4Ϯ0.2 mV in isoproterenol (nϭ4, PϽ0.01). The slope factor was 10.9Ϯ0.5 mV in control and 11.0Ϯ0.2 mV in isoproterenol (PϾ0.05). Using a two-pulse protocol to illustrate the shift in activation, the time-dependent current in the presence of isoproterenol is larger in response to the first step than control and smaller in response to the second step ( Figure 3C ). This is consistent with an ISO-induced positive shift in I f activation. Acetylcholine had no direct effect on the time-dependent current (nϭ3), due either to the absence of muscarinic receptors or to a low basal level of cAMP that could not be further reduced by acetylcholine inhibition of adenylyl cyclase. We therefore further tested whether acetylcholine could reverse the actions of isoproterenol (Figure 4) . Examination of the response to the step hyperpolarizations to Ϫ80 and Ϫ100 mV indicate that addition of acetylcholine reduces the membrane currents. However, they are almost identical at Ϫ160 mV ( Figures 4A  and 4B ), consistent with a negative shift in activation induced by acetylcholine. Figure 4D shows the activation curves in isoproterenol and isoproterenolϩacetylcholine. The V 50 s were Ϫ91.3Ϯ1.1 mV for isoproterenol and Ϫ106.6Ϯ0.8 mV for isoproterenolϩacetylcholine (nϭ3, PϽ0.05). The slope factors were 14.6Ϯ0.9 mV in isoproterenol and 11.1Ϯ0.9 mV (nϭ3, PϽ0.05). We also used a two-pulse protocol ( Figure  4C ). The response to the first voltage step is larger in isoproterenol than in isoproterenolϩacetylcholine, whereas the reverse is true for the second step. This is again consistent with a negative shift in activation induced by addition of acetylcholine. These results demonstrate that the hMSCs transfected with mHCN2 should respond to ␤-adrenergic and muscarinic agonists.
mHCN2-Transfected hMSCs Modulation of Impulse Initiation by Cardiac Myocytes
Having expressed the pacemaker gene in hMSCs, we hypothesized that the mHCN2-transfected hMSCs could influence excitability of coupled heart cells. Maximum diastolic potential was Ϫ74Ϯ1 mV (nϭ5) in neonatal rat ventricular myocytes cocultured with EGFP expressing hMSCs and Ϫ67Ϯ2 mV (nϭ6) in myocytes cocultured with hMSCs expressing mHCN2 (PϽ0.05). Spontaneous rate was 93Ϯ16 bpm in the former group (nϭ5) and 161Ϯ4 bpm in the latter (nϭ6, PϽ0.05). The reduced maximum diastolic potential is consistent with the observed threshold potential of the ex- Ϫ6 mol/L (B). C, Voltage dependence of activation of I f in control, ISO, and washout using a two-step pulse protocol. D, Boltzmann fit to the normalized density of tail currents. Activation curve was constructed with the same protocol as in Figure 1 . Two-pulse protocol was initiated from a holding potential of Ϫ30 mV. First step was to Ϫ100 mV for 1.5 seconds followed by a second step to Ϫ150 mV for 1 second. Voltage was then stepped to ϩ15 mV for 1 second to rapidly deactivate the current and then returned to the holding potential. pressed current in the mHCN2-transfected hMSCs, and indicates the influence of this depolarizing current on the electrically coupled myocytes. Representative action potentials are shown in Figure 5 .
mHCN2-Transfected hMSCs as a Biological Pacemaker in Intact Canine Heart
Given the demonstration of functional coupling of mHCN2-expressing hMSCs to myocytes in vitro, we then injected them into canine heart in situ (see Materials and Methods) to test whether pacemaker function was demonstrable. During sinus arrest, escape pacemaker function can originate in the left or right ventricle, as occurred here, with two of four animals receiving hMSCs expressing EGFP alone developing left and two developing right ventricular escape rhythms. In contrast, five of six animals receiving hMSCs expressing EGFPϩmHCN2 developed rhythms originating from and pace-mapped to the left ventricle at a site whose origin approximated that of the hMSC injection. Moreover, the idioventricular rates of these animals was 61Ϯ5 versus 45Ϯ1 bpm in animals receiving hMSCs expressing EGFP alone (PϽ0.05). A representative experiment is shown in Figure 6 .
Hematoxylin and eosin stain of the site of hMSCs injection revealed normal cardiac myocytes and dense areas of basophilic infiltration adjacent to the needle track ( Figure 7A ). The hMSCs were easily identified by their size (10 to 20 m in diameter), large hyperchromatic nuclei, and scanty, deeply basophilic cytoplasm with no matrix. Although the hMSCs had a characteristic appearance with H&E staining, they were more precisely identified by using immunohistochemical stains. The hMSCs stained intensely for vimentin (eg, Figure  7B ), a marker of cells of mesenchymal origin. The same regions also were positive for human CD44 (eg, Figure 7C ). Interdigitation between hMSCs and myocardium was very clear (eg, Figure 7D ).
hMSCs Form Gap Junctions With Cardiac Myocytes In Vitro and In Vivo
To test whether the hMSCs couple electrically with cardiac myocytes, we cocultured hMSCs with adult canine ventricular myocytes. Myocytes were dissociated and plated for between 12 and 72 hours before coculture with hMSCs. Measurement of coupling occurred 6 to 12 hours after adding hMSCs to the myocyte culture. Our preliminary observations reveal that stem cells couple to cardiac cells. Figure 8A illustrates one example of an hMSC-myocyte pair in coculture; it is one of four so far observed. For heterologous pairs identification the hMSCs were tagged with Cell Tracker green (Molecular Probes). 11 A bipolar voltage-ramp protocol was used to alter transjunctional voltage V j (V 2 ϪV 1 ) over Ϯ100 mV range at 200 mV/15-second rate (see V 1 and V 2 ) and is shown in Figure 8B . The ramp pulse was applied to the myocyte (V 1 ) while membrane potential of the hMSC was kept at 0 mV (V 2 ). The associated sister currents, I 1 and I 2 , were recorded from the myocyte and hMSC, respectively. The currents followed the voltage-ramp profile demonstrating gap junction coupling of the heterologous hMSC-myocyte pair. The current, I 2 , obtained from the nonstepped hMSC, reflects a coupling current, I j . This record demonstrates effective coupling of the hMSC to the ventricular myocyte. Figure 8C shows immunohistochemical staining with antiCx43 antibodies of the site of the injection of hMSCs into the canine heart. Intercalated discs are revealed in the myocardium (see purple arrow), whereas small punctate staining for Cx43 is seen between hMSCs (white arrows). There is also Cx43 staining at interfaces between hMSCs and myocytes (red arrows). The inset of Figure 8C shows a section from a piece of myocardium (fixed in 4% paraformaldehyde in 0.1 mol/L phosphate buffer at pH of 7.4 at 4°C and subsequently treated as described by Walcott et al 19 ) injected with hMSCs expressing EGFP plus HCN2. The red staining from the secondary antibody to EGFP illustrates localization of hMSCs, whereas the blue staining illustrates cell nuclei. A significant majority of the clustered cells are hMSCs.
Discussion
Pacemaker implantation is a primary treatment for complete heart block or sinus node dysfunction. The current therapy uses electronic devices with high reliability and low morbidity. Nevertheless, such devices are not optimal because they lack the biological responsiveness of native tissues. Recently several approaches have been attempted to provide biological pacemaker function. Included among these attempts have been an upregulation of ␤ 2 -adrenergic receptors, a downregulation of the background K ϩ current I K1 and our own previous studies with overexpression of the HCN2 gene, the molecular correlate of the endogenous cardiac pacemaker current I f . [2] [3] [4] [5] [6] In these latter studies, we showed that HCN2 overexpression locally in left atrium or in the proximal bundle-branch system induces both I f -like currents and in situ pacemaker function in the recipient myocytes. The unique voltage dependence of the I f conductance results in current flow during diastole but not during the action potential plateau, limiting possible complications attendant to significant alterations of the action potential waveform. Although an adenoviral construct has been used to deliver the HCN2 gene to the heart, 5,6 this approach is not optimal because adenoviruses are episomal and the nucleic acids they deliver do not integrate into genome. Other viral systems are accompanied by a number of serious drawbacks that hinder their use in vivo.
An alternative means for fabricating biological pacemakers is via embryonic stem cells, which can be differentiated along a cardiac lineage and might provide a platform for cell-based control of cardiac rhythm. Embryonic stem cells can make functional gap junctions and generate spontaneous electrical activity. 20 However because of their immunogenicity, rejection is a serious consideration. Moreover, as with hMSCs, embryonic stem cell preparations are not spatially uniform and the proper engineering of both cell-based systems presents a challenge in designing in vivo biological pacemakers.
For several reasons, hMSCs are an attractive cellular vehicle for gene delivery applications. They can be obtained in relatively large numbers through a standard clinical procedure. hMSCs are easily expanded in culture and capable of long-term transgene expression. 21 Their administration can be autologous or via banked stores, given evidence that they may be immunopriviliged. 22 Long-term function of such a pacemaker is based on prolonged expression of mHCN2, which in turn requires integration into the genome of hMSCs. Random integration increases the possibility of disruption of genes involved in the cell cycle or tumor suppression, or may cause epigenetic changes. However, the ex vivo transfection method used here allows the DNA integration site to be evaluated before use and the cell carriers can be engineered with fail-safe death mechanisms.
The objective of this study was to test the feasibility of using genetically modified hMSCs as a platform for systemic delivery of pacemaker genes into the heart. HCN2 served as the model system for this study. Our genetically engineered hMSCs expressed an I f -like current and were capable of increasing the spontaneous beating rate of cocultured rat neonatal myocytes and originating a ventricular rhythm during vagally induced sinus arrest in the canine heart. Control hMSCs expressing only EGFP did not exert these effects either in vitro or in vivo. Thus, the electrical effects of the hMSCs transfected with the mHCN2 gene were similar to the effects of overexpression of the same gene in the myocytes in in vitro and in vivo systems. These findings suggest that hMSCs may serve as an alternative approach for the delivery of pacemaker genes for cardiac implantation.
In sinus node myocytes the HCN gene generates an inward current necessary for cardiac excitation. Unlike sinoatrial node cells, mHCN2-transfected hMSCs are not excitable, because they lack the other currents required to generate an action potential. However, these cells are able to generate a depolarizing current, which spreads to coupled myocytes, driving myocytes to threshold. Our hypothesis is that as long as the hMSCs contain the pacemaker gene and couple to cardiac myocytes via gap junctions, they will function as a cardiac pacemaker in an analogous manner to the normal primary pacemaker the sinoatrial node. We demonstrated using dual patch technique that hMSCs form gap junctions that couple electrically with canine cardiac myocytes. The coupling between engrafted hMSCs and cardiac myocytes was also shown by immunohistochemical staining of the tissues isolated from the site of hMSC injection using anti-connexin 43 antibodies. Within an injection site, the clusters of cells were vimentin and CD44 positive, and we also demonstrated that a significant majority of the cluster of cells were EGFP positive, thereby confirming their identity as hMSCs. A recent report has suggested that mouse MSCs can fuse with mouse myocytes in vivo with a fusion rate of 0.005%. 23 We have not ruled this possibility out in our studies, but at the fusion rate reported by Morimoto et al, 23 only 50 hMSCs of the million cells injected would fuse.
There are limitations to the approach used in this study. First, the hMSCs were delivered to the free wall myocardium, not an optimal site for ordered contraction. However, we have recently used catheter approaches to insert pacemaker genes into the canine left bundle branch system. 6 Such a locus offers the possibility of more ordered and normal activation and contraction than is the case with a pacemaker residing in the free wall. Before this approach is used for hMSCs, catheter modification may need to occur to optimize injection of cells of the size of an hMSC without cell injury or destruction.
Another question relates to the duration of efficacy of these pacemakers. In the present study, we were only concerned with demonstrating the feasibility of using hMSCs as a gene delivery system. Because our studies in vivo lasted only 3 to 10 days, transient transfections were sufficient. Before this approach can be considered clinically relevant, far longer periods of study will be required. In this regard, our transfected cells maintain their green fluorescence for at least 3 months when grown on antibiotic to select stably expressing cells. This indicates that we have selected for stable clones expressing mHCN2, so it is likely that persistence of expression will not pose significant difficulties for more prolonged Figure 8 . Gap junctions between an hMSC-canine ventricular myocyte pair. A, Phase-contrast micrograph of a hMSCmyocyte pair and locations of pipettes 1 and 2. B, Voltage ramp (V 1 ϭϮ100 mV; V 2 ϭ0) applied to the canine myocyte evoked current flow through the patch pipettes attached in whole-cell mode to the myocyte, I 1 , and hMSC, I 2 . Currents recorded from the stepped myocyte, I 1 , represent the sum of two components, a junctional current and a membrane current in the myocyte. The mirror current, I 2 , recorded from the nonstepped hMSC corresponds to the junctional current, I j , between the hMSCmyocyte pair. C, Immunostaining for Cx43 in a region of interface between an injection site and myocardium. DAPI staining reveals nuclei. Arrows are purple, intercalated discs; white, Cx43 staining between hMSCs; red, Cx43 staining between hMSCs and myocytes. Inset, DAPI and EGFP antibody staining of a section from another animal, which was subjected to paraformaldehyde fixation and immunostained with anti-EGFP and DAPI to verify that injection sites contained hMSCs. M indicates myocardium; S, hMSC. studies. However, it remains to be determined if the differentiation state of the hMSCs is altered in situ in the long term, or whether such differentiation would affect mHCN2 expression or biophysical properties. In addition, a murine gene, which is quite close but not completely identical in sequence to the human gene was used here. Not only would it be most advantageous to use human genes, but the exploration of various mutations to optimize activation and recovery characteristics, as well as neurohumoral response would be desirable. Such approaches are currently being explored.
In closing, the delivery of hMSCs expressing mHCN2 to the canine heart is not only a demonstration of feasibility of preparing hMSC-based biological pacemakers, but is the first concrete example of a general principle: hMSCs can be used to deliver a variety of genes to influence the function of syncytial tissues. One alternative potential cardiovascular application is delivery of K ϩ channel genes to hyperpolarize vascular smooth muscle inducing relaxation. Indeed, the payload delivered by hMSCs need not be restricted to membrane channels: any gene product or small molecule that can permeate gap junctions (MW Ͻ1000, minor diameter Ͻ1.2.nm) can be incorporated into the hMSCs and delivered to a syncytial tissue as its therapeutic target.
